[Suspected S-1-Induced Rhabdomyolysis during Adjuvant Chemotherapy after Breast Cancer Surgery-A Case Report].
Аннотация
Based on the POTENT trial results, S-1, an oral fluoropyrimidine, is used in the adjuvant setting for various cancers, including hormone receptor-positive and HER2-negative breast cancers. Although S-1 is generally well tolerated, rare but serious adverse effects, such as rhabdomyolysis, have been reported. We present a case of suspected S-1-induced rhabdomyolysis in a 56-year-old woman with a history of hypertension and dyslipidemia, who was taking amlodipine besilate and pravastatin sodium. Sixteen months prior, she underwent nipple-sparing mastectomy with axillary dissection and TRAM flap reconstruction for right breast cancer. Following dose-dense EC therapy and discontinuation of docetaxel owing to drug-induced pneumonitis, she began adjuvant therapy with letrozole and S-1. Serum creatine kinase(CK)level progressively increased, peaking at 4,419 U/L during the 14th course, accompanied by myalgia. After discontinuation of S-1, the CK level returned to normal despite the continuation of other medications. No other obvious cause of rhabdomyolysis was identified. Given the temporal relationship and resolution upon drug withdrawal, S-1 was considered the likely causative agent. Although extremely rare, clinicians should be aware of the potential for S-1-induced rhabdomyolysis and monitor for muscle-related symptoms during treatment.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.